Support our Research
Need a prospectus? Order one here.
Buckingham Institute for Translational Medicine
The Buckingham Institute for Translational Medicine is based within the Clore Laboratory, and is an internationally recognised research group with a track record in drug discovery, including beta3-adrenoceptor agonists for obesity, orexin and MCH-antagonists, and the insulin sensitiser drug rosiglitazone. The late Mike Cawthorne was awarded the 2001 Society for Medicines Research award for drug discovery in recognition of his work on the discovery of rosiglitazone.
In 2016 Professor Krentz assumed the role of Director from Professor Paul Trayhurn, who had been acting as interim Director since 2015. Professor Krentz is a senior endocrinologist and clinical scientist with expertise in diabetes, clinical metabolic research, and knowledge of early phase development of new drugs and devices for diabetes. Professor Krentz has a track record of translational research in diabetes that has resulted in changes to clinical practice.
Dr Tadayyon has recently joined Clore Life Sciences as Deputy Director after a successful career in diabetes drug discovery and drug development, in particular co-discovery, pre-clinical development and early clinical assessment of the anti-diabetic DPP-4 inhibitor linagliptin. Dr Tadayyon was involved in the identification of GPR40 as a potential target for type 2 diabetes and supported efforts to characterize the role of orexins and other peptides in appetite and body weight regulation. A major focus for Dr Tadayyon will be on developing new relationships with the biopharmaceutical industry.
Our focus is encompassed by 3 research themes, which highlight our combined basic research, drug discovery and clinical expertise. The aim of our pre-clinical research is to inform drug development and enhance underlying biological understanding. Through interaction with the Medical School and our long-standing academic, clinical and pharmaceutical collaborations we are translating our key research themes into clinical studies and ultimately therapeutics.
- Diabetes, Obesity and Metabolic Disease
- Biomedical Informatics and Digital Health Technology